1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
61F988D5BF9DA062A00258A99003AF3D6
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/establishing-latam-standards-field-medical-performance-excellence?opendocument
18
19opendocument
2034.239.151.124
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25BMR




» Products & Services » » Medical Affairs » Field Medical Excellence

Establishing LATAM Standards for Field Medical Performance Excellence

ID: POP-377


Features:

9 Info Graphics

19 Data Graphics

310+ Metrics

9 Narratives


Pages: 33


Published: 2024


Delivery Format: Shipped


 

License Options:


Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
To achieve high impact within each of the diverse Latin American (LATAM) markets, biopharma manufacturers must focus on standardizing and improving the capabilities of their field medical teams. To do this, field medical leaders must identify and select the right key performance indicators, engagement frameworks, and tactics that will drive impactful stakeholder engagement.

Best Practices, LLC undertook this benchmarking research to provide actionable strategies to field medical leaders, empowering them to navigate different challenges and capitalize on opportunities within the LATAM market. By delving into key insights and benchmarks, our report offers a roadmap for optimizing field medical operations in Latin America.

Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Biopharmaceutical; Manufacturing; Biotech; Consumer Products; Medical Device; Chemical; Clinical Research; Laboratories


Companies Profiled:
Abbott; AbbVie; Alexion Pharmaceuticals; Alkermes; Astellas; AstraZeneca; Bayer; BioMarin; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chiesi; Clovis Oncology; CSL Behring; Curis; Daiichi Sankyo; Dermavant Sciences; Dompé; Eisai; Eurofarma; Exact Sciences; Galapagos; GE Healthcare; Genentech; Gilead Sciences; GlaxoSmithKline ; Grünenthal; Horizon Therapeutics; Ipsen; Janssen; Jazz Pharmaceuticals; Kyowa Kirin; Lundbeck; Merck; Merck KGaA; Merus; Novartis; Novo Nordisk; OM Pharma; Orchard Therapeutics; Pfizer; Radius Health; Inc.; Sanofi; Seres Therapeutics; Servier; Sunovion; Supernus; Takeda Pharmaceuticals; Teva Pharmaceutical Industries Ltd; UCB Pharma; Ultragenyx; Vertex Pharmaceuticals

Study Snapshot

This report provides benchmarks and insights specific to the LATAM region. The data from this study is drawn from a larger global pool of field leaders, featuring 448 survey responses from 100+ biopharma manufacturers worldwide. The data is meticulously segmented at the regional level to provide nuanced insights.

Best Practices, LLC also leveraged its propriety Field Medical Excellence database to provide additional benchmarks tailored to align with diverse portfolio considerations.

Key topics covered in this report include:

  • Effective Field Performance Metrics in the LATAM Region
  • Field Medical Excellence Framework
  • Target and Engagement Levels of KOLs in the LATAM Region
  • Average MSL Time Spent in KOL Interactions and on Internal Activities
  • Field Medical Staffing Footprint in the LATAM Region
  • Key Lessons Learned for Measuring MSL Impact in the LATAM Region

Key Findings

Select key insights uncovered from this report are noted below. Detailed findings are available in the full report.

  • Tracking Non-Tiered KOL Engagement: In LATAM, the majority of field medical teams do not utilize specific metrics to monitor non-tiered KOL engagement on panels, with only 33% of companies incorporating such measures.
Table of Contents

Sr. No.
Topic
Slide No.
I.
Executive Summary: Laying the Foundation for Global Field Medical Performance Standards & ExpectationsPg. 3-17
II.
LATAM: Region-level benchmarksPg. 18-32
III.
About Best Practices, LLCPg. 33

    List of Charts & Exhibits

    I. Executive Summary: Laying the Foundation for Global Field Medical Performance Standards & Expectations

    • Business objectives and research methodology used
    • Regions examined in this benchmark study
    • Participating benchmark companies
    • Global benchmarking findings: Quick takeaways and recommendations
    • Summary of regional data: LATAM
    • Most effective and utilized field metrics for assessing and demonstrating the value of MSLs
    • Defining “monthly interactions”
    • Distinguishing an "actionable" insight from other kinds of insights
    • Definitions of "actionable insights" from the field
      Crafting a global framework for excellence in field medical engagement
    • Metrics to assess MSL performance
    • Lessons learned around MSL time allocation in the field and on external activities

    II. LATAM

    • Average total panel size supported by an individual MSL in the LATAM region
    • Average number of monthly KOL/HCP and F2F meetings in the LATAM region
    • MSL’s average time spent per thought leader interaction in the LATAM region
    • Value assigned to each interaction type on the MSL scorecard – LATAM region
    • Key metrics for evaluating and demonstrating the value of MSLs in the LATAM region
    • Engagement metrics for non-tiered KOLs in the LATAM region
    • Average annual field presence of MSLs in the LATAM region
    • Time spent by MSLs on external, internal and logistics activities in the LATAM region
    • Weekly MSL time allocation across activity streams in the LATAM region
    • MSL engagement mix in the LATAM region
    • Average number of field staff members in the LATAM region
    • Span of control: MSLs per MSL manager in the LATAM region